ruxolitinib sustained release (INCB018424 SR) / Incyte - LARVOL DELTA

Development and Evaluation of Bilayer Sustained-Release Tablets of Ruxolitinib Using Discriminative Pharmacokinetic Analysis and IVIVC. (PubMed, Pharmaceutics) - "Pharmacokinetic studies showed that test formulation F4, which has a 20:20 IR-to-SR ratio, is expected to provide a similar area under the curve (AUC) while prolonging exposure compared to the reference IR tablet. This study highlights the potential of a bilayer tablet approach, combined with discriminative pharmacokinetic and IVIVC analysis, for creating a sustained-release dosage form of ruxolitinib."

Journal • PK/PD data

Evaluating Ruxolitinib in Steroid Refractory Chronic GvHD : Episode 5: Use of Subsequent Therapies in SR/D cGvHD (Targeted Oncology) - "Experts discuss the treatments for steroid-refractory/dependent chronic Graft vs Host Disease (SR/D cGvHD), focusing on the unique mechanisms and applications of belumosudil and role of ibrutinib."

Video